Bad news last week from the FDA for cash-strapped Vion Pharmaceuticals Inc. regarding Onrigin pointed up the need for a better therapy against acute myeloid leukemia in the elderly as well as the difficulty in developing one that works and can pass muster with regulators. Read More
